Drugs / GI-5005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00124215 | Jun 2005 → Jun 2007 | chronic hepatitis C virus infection | GlobeImmune | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00606086 | Dec 2007 → Nov 2012 | chronic hepatitis C virus infection | GlobeImmune | Completed | Missed primary |
Press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GI-5005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00124215 ↗ |
| Modality | Vaccine | “The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects.” NCT00124215 ↗ |
| Route | Subcutaneous | “injected under the skin” NCT00124215 ↗ |